Published in Nat Med on October 01, 2003
Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis (2010) 10.97
The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science (2011) 4.76
Cytokine signaling modules in inflammatory responses. Immunity (2008) 4.09
Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest (2008) 3.90
Tumor necrosis factor-alpha triggers a cytokine cascade yielding postoperative cognitive decline. Proc Natl Acad Sci U S A (2010) 2.70
Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A (2005) 2.47
Human malarial disease: a consequence of inflammatory cytokine release. Malar J (2006) 2.36
Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax (2005) 2.19
Alarmins: awaiting a clinical response. J Clin Invest (2012) 2.19
Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol (2009) 2.06
Expanded CD23(+)/CD21(hi) B cells in inflamed lymph nodes are associated with the onset of inflammatory-erosive arthritis in TNF-transgenic mice and are targets of anti-CD20 therapy. J Immunol (2010) 1.94
The future of pharmacology. Br J Pharmacol (2006) 1.85
Immediate mediators of the inflammatory response are poised for gene activation through RNA polymerase II stalling. Proc Natl Acad Sci U S A (2009) 1.83
Gene-specific control of the TLR-induced inflammatory response. Clin Immunol (2008) 1.80
Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner. Nat Med (2009) 1.70
Longitudinal assessment of synovial, lymph node, and bone volumes in inflammatory arthritis in mice by in vivo magnetic resonance imaging and microfocal computed tomography. Arthritis Rheum (2007) 1.68
Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann Rheum Dis (2006) 1.62
TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. MedGenMed (2006) 1.56
Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med (2008) 1.51
Transcription factor T-bet regulates inflammatory arthritis through its function in dendritic cells. J Clin Invest (2006) 1.49
Human tumour necrosis factor: physiological and pathological roles in placenta and endometrium. Placenta (2008) 1.43
A Rationally Designed TNF-α Epitope-Scaffold Immunogen Induces Sustained Antibody Response and Alleviates Collagen-Induced Arthritis in Mice. PLoS One (2016) 1.40
Treating very early rheumatoid arthritis. Best Pract Res Clin Rheumatol (2006) 1.34
Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy. Arthritis Res Ther (2011) 1.33
Treatment of rheumatoid arthritis. BMJ (2006) 1.30
Collagen-induced arthritis in C57BL/6 mice is associated with a robust and sustained T-cell response to type II collagen. Arthritis Res Ther (2007) 1.29
Nuanced roles of cytokines in three major human brain disorders. J Clin Invest (2008) 1.28
Gene silencing in severe systemic inflammation. Am J Respir Crit Care Med (2007) 1.27
Molecular profile of peripheral blood mononuclear cells from patients with rheumatoid arthritis. Mol Med (2007) 1.24
TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation. Proc Natl Acad Sci U S A (2006) 1.21
Progranulin: a promising therapeutic target for rheumatoid arthritis. FEBS Lett (2011) 1.20
Gene-specific epigenetic regulation in serious infections with systemic inflammation. J Innate Immun (2010) 1.17
The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther (2009) 1.15
Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. Arthritis Res Ther (2010) 1.14
Elucidating bone marrow edema and myelopoiesis in murine arthritis using contrast-enhanced magnetic resonance imaging. Arthritis Rheum (2008) 1.14
IL-10 inhibits transcription elongation of the human TNF gene in primary macrophages. J Exp Med (2010) 1.07
Regulatory multitasking of tolerogenic dendritic cells - lessons taken from vitamin d3-treated tolerogenic dendritic cells. Front Immunol (2013) 1.06
Stimulation of proteoglycan synthesis by glucuronosyltransferase-I gene delivery: a strategy to promote cartilage repair. Proc Natl Acad Sci U S A (2004) 1.05
Efficacy of B cell depletion therapy for murine joint arthritis flare is associated with increased lymphatic flow. Arthritis Rheum (2013) 1.05
Integrative modeling of transcriptional regulation in response to antirheumatic therapy. BMC Bioinformatics (2009) 1.04
Effects of a physical activity behavior change intervention on inflammation and related health outcomes in breast cancer survivors: pilot randomized trial. Integr Cancer Ther (2012) 1.03
Unraveling the signaling pathways promoting fibrosis in Dupuytren's disease reveals TNF as a therapeutic target. Proc Natl Acad Sci U S A (2013) 1.03
Fine-tuning of dendritic cell biology by the TNF superfamily. Nat Rev Immunol (2012) 1.02
The role of the T cell in age-related inflammation. Age (Dordr) (2012) 1.00
Synthesis and characterization of a thermally-responsive tumor necrosis factor antagonist. J Control Release (2008) 0.99
Suppressor of cytokine signalling protein SOCS3 expression is increased at sites of acute and chronic inflammation. J Mol Histol (2011) 0.99
Enriching the human apoptosis pathway by predicting the structures of protein-protein complexes. J Struct Biol (2012) 0.98
Enhanced COMP catabolism detected in serum of patients with arthritis and animal disease models through a novel capture ELISA. Osteoarthritis Cartilage (2012) 0.98
The oxazolidinone derivative locostatin induces cytokine appeasement. J Immunol (2009) 0.97
Lipopolysaccharide inhibits macrophage phagocytosis of apoptotic neutrophils by regulating the production of tumour necrosis factor α and growth arrest-specific gene 6. Immunology (2010) 0.95
The future of osteoarthritis therapeutics: emerging biological therapy. Curr Rheumatol Rep (2013) 0.95
Phosphorylation of the ARE-binding protein DAZAP1 by ERK2 induces its dissociation from DAZ. Biochem J (2006) 0.94
Modulation of postoperative cognitive decline via blockade of inflammatory cytokines outside the brain. Proc Natl Acad Sci U S A (2010) 0.91
Guilt by association - what is the true risk of malignancy in children treated with etanercept for JIA? Pediatr Rheumatol Online J (2010) 0.91
Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases. Int Immunol (2015) 0.91
Two coordinated mechanisms underlie tumor necrosis factor alpha-induced immediate and delayed IκB kinase activation. Mol Cell Biol (2013) 0.91
Macrophage heterogeneity in the context of rheumatoid arthritis. Nat Rev Rheumatol (2016) 0.91
Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali(®)) Versus Etanercept (Enbrel(®)) - Findings from a Nurse Survey in Europe. Rheumatol Ther (2016) 0.91
Resistance to regulatory T cell-mediated suppression in rheumatoid arthritis can be bypassed by ectopic foxp3 expression in pathogenic synovial T cells. Proc Natl Acad Sci U S A (2011) 0.90
Rhesus macaque theta defensins suppress inflammatory cytokines and enhance survival in mouse models of bacteremic sepsis. PLoS One (2012) 0.89
Delayed apoptosis of human monocytes exposed to immune complexes is reversed by oxaprozin: role of the Akt/IkappaB kinase/nuclear factor kappaB pathway. Br J Pharmacol (2009) 0.89
Phosphodiesterase 4-targeted treatments for autoimmune diseases. BMC Med (2013) 0.88
Development of type 1 diabetes in a patient treated with anti-TNF-alpha therapy for active rheumatoid arthritis. Diabetologia (2009) 0.88
Differential effects of total and partial neutralization of tumor necrosis factor on cell-mediated immunity to Mycobacterium bovis BCG infection. Infect Immun (2005) 0.88
OX40L blockade is therapeutic in arthritis, despite promoting osteoclastogenesis. Proc Natl Acad Sci U S A (2014) 0.86
Could toll-like receptors provide a missing link in chronic inflammation in rheumatoid arthritis? Lessons from a study on human rheumatoid tissue. Ann Rheum Dis (2007) 0.86
Effect of anti-rheumatic agents on periodontal parameters and biomarkers of inflammation: a systematic review and meta-analysis. J Periodontal Implant Sci (2012) 0.86
A ceramide-1-phosphate analogue, PCERA-1, simultaneously suppresses tumour necrosis factor-alpha and induces interleukin-10 production in activated macrophages. Immunology (2009) 0.85
Regulation of early cartilage destruction in inflammatory arthritis by death receptor 3. Arthritis Rheumatol (2014) 0.85
TNF-α gene silencing using polymerized siRNA/thiolated glycol chitosan nanoparticles for rheumatoid arthritis. Mol Ther (2013) 0.84
Goal-directed treatment of osteoporosis in Europe. Osteoporos Int (2014) 0.84
Myeloid suppressor cells require membrane TNFR2 expression for suppressive activity. Immun Inflamm Dis (2014) 0.83
Signaling transduction analysis in gingival epithelial cells after infection with Aggregatibacter actinomycetemcomitans. Mol Oral Microbiol (2011) 0.83
If the treatment works, do we need to know why?: the promise of immunotherapy for experimental medicine. J Exp Med (2007) 0.82
Recommendation for optimal management of severe refractory asthma. J Asthma Allergy (2010) 0.81
TNFR1-induced lethal inflammation is mediated by goblet and Paneth cell dysfunction. Mucosal Immunol (2014) 0.81
Selective Inhibition of Membrane Type 1 Matrix Metalloproteinase Abrogates Progression of Experimental Inflammatory Arthritis: Synergy With Tumor Necrosis Factor Blockade. Arthritis Rheumatol (2016) 0.81
Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion. J Exp Med (2016) 0.80
Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis. Eur J Immunol (2014) 0.80
Immune regulation by CD52-expressing CD4 T cells. Cell Mol Immunol (2013) 0.80
Bosentan, an endothelin receptor antagonist, ameliorates collagen-induced arthritis: the role of TNF-α in the induction of endothelin system genes. Inflamm Res (2012) 0.80
Inactivation of DAP12 in PMN inhibits TREM1-mediated activation in rheumatoid arthritis. PLoS One (2015) 0.80
The Role of Th17 in Neuroimmune Disorders: A Target for CAM Therapy. Part III. Evid Based Complement Alternat Med (2011) 0.80
Inching towards a targeted therapy for preeclampsia. Hypertension (2009) 0.80
Anti-TNF in rheumatoid arthritis: an overview. Wien Med Wochenschr (2015) 0.80
Selective targeted delivery of the TNF-alpha receptor p75 and uteroglobin to the vasculature of inflamed tissues: a preliminary report. BMC Biotechnol (2011) 0.79
Protective effects of indomethacin and cyclophosphamide but not of infliximab on liver metabolic changes caused by adjuvant-induced arthritis. Inflammation (2011) 0.79
Toad glandular secretions and skin extractions as anti-inflammatory and anticancer agents. Evid Based Complement Alternat Med (2014) 0.79
The role of bone marrow edema and lymphangiogenesis in inflammatory-erosive arthritis. Adv Exp Med Biol (2010) 0.79
Antibody engineering & therapeutics, the annual meeting of the antibody society December 7-10, 2015, San Diego, CA, USA. MAbs (2016) 0.78
B cell epitopes on infliximab identified by oligopeptide microarray with unprocessed patient sera. J Transl Med (2015) 0.78
Pharmacokinetic and Pharmacodynamic Characterisation of an Anti-Mouse TNF Receptor 1 Domain Antibody Formatted for In Vivo Half-Life Extension. PLoS One (2015) 0.78
A novel small-molecule tumor necrosis factor α inhibitor attenuates inflammation in a hepatitis mouse model. J Biol Chem (2014) 0.78
Genetic association of TNF-α-308 G/A and -863 C/A polymorphisms with late onset Alzheimer's disease in Azeri Turk population of Iran. J Res Med Sci (2011) 0.78
Crystallization and preliminary X-ray analysis of the tumour necrosis factor alpha-tumour necrosis factor receptor type 2 complex. Acta Crystallogr Sect F Struct Biol Cryst Commun (2009) 0.77
Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor. J Exp Med (2016) 0.77
Melittin-glutathione S-transferase fusion protein exhibits anti-inflammatory properties and minimal toxicity. Eur J Pharm Sci (2014) 0.77
Fullerenes and their derivatives as inhibitors of tumor necrosis factor-α with highly promoted affinities. J Mol Model (2016) 0.77
Deciphering Asthma Biomarkers with Protein Profiling Technology. Int J Inflam (2015) 0.76
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum (2004) 6.22
Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum (2006) 3.29
Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Arthritis Rheum (2006) 1.36
Interleukin-6: a new therapeutic target. Arthritis Res Ther (2006) 1.36
The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. Best Pract Res Clin Rheumatol (2004) 1.26
Cytokines and anti-cytokine biologicals in autoimmunity: present and future. Cytokine Growth Factor Rev (2002) 1.18
Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us? J Immunol (2010) 1.14
Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies. Joint Bone Spine (2002) 1.11
Anti-TNF therapy: where have we got to in 2005? J Autoimmun (2005) 1.07
A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. III. Comparative performance characteristics of academic and manufacturers' laboratories. J Rheumatol (2003) 0.93
The pitfalls in the development of biologic therapy. Nat Clin Pract Rheumatol (2007) 0.88
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum (2008) 0.80
Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease? Novartis Found Symp (2004) 0.79
Blocking tumor necrosis factor inhibits radiographic damage even in patients who show minimal or no clinical improvement: comment on the concise communication by Boers. Arthritis Rheum (2002) 0.79
A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. II. Potential for quantitation of antibody content. J Rheumatol (2002) 0.78
Introducing Arthritis Research & Therapy's 10th anniversary issue, 'The Scientific Basis of Rheumatology: A Decade of Progress'. Arthritis Res Ther (2008) 0.75